Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.

Roex, Gils; Feys, Tom; Beguin, Yves; Kerre, Tessa; Poiré, Xavier; Lewalle, Philippe; Vandenberghe, Peter; Bron, Dominique; Anguille, Sébastien.

Affiliation

Roex G; Tumor Immunology Group, Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650 Edegem, Belgium.
Feys T; Ariez International BV, 9000 Ghent, Belgium.
Beguin Y; Department of Hematology, University of Liège, 4000 Liège, Belgium.
Kerre T; Department of Hematology, University Hospital Ghent, 9000 Ghent, Belgium.
Poiré X; Faculty of Medicine and Dentistry, Université Catholique de Louvain, 1200 Woluwe-Saint-Lambert, Belgium.
Lewalle P; Department of Hematology, Institut Jules Bordet, 1000 Brussels, Belgium.
Vandenberghe P; Department of Hematology, University Hospitals Leuven, 3000 Leuven, Belgium.
Bron D; Department of Hematology, Institut Jules Bordet, 1000 Brussels, Belgium.
Anguille S; Tumor Immunology Group, Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650 Edegem, Belgium.

Pharmaceutics ; 12(2)2020 Feb 24.

Article in En | MEDLINE | ID: mdl-32102267

ABSTRACT

Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.

Key words

B-cell malignancies; BCMA; CAR-T cells; CD19; immunotherapy